Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.265,60
0,39%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Pyxis Oncology Inc (PYXS) Pyxis Oncology Inc (PYXS) Notizie

PYXS

Pyxis Oncology (PYXS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PYXS
DataOraFonteTitoloSimboloCompagnia
12/06/202422:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PYXSPyxis Oncology Inc
10/06/202413:30GlobeNewswire Inc.Pyxis Oncology Expands Board of Directors with Appointment of Michael A. MetzgerNASDAQ:PYXSPyxis Oncology Inc
07/06/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
30/05/202413:30GlobeNewswire Inc.Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceNASDAQ:PYXSPyxis Oncology Inc
14/05/202414:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PYXSPyxis Oncology Inc
14/05/202413:30GlobeNewswire Inc.Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024NASDAQ:PYXSPyxis Oncology Inc
09/05/202413:30GlobeNewswire Inc.Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:PYXSPyxis Oncology Inc
28/03/202421:30GlobeNewswire Inc.Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PYXSPyxis Oncology Inc
27/03/202412:30GlobeNewswire Inc.Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty RightsNASDAQ:PYXSPyxis Oncology Inc
21/03/202412:30GlobeNewswire Inc.Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023NASDAQ:PYXSPyxis Oncology Inc
13/03/202413:00GlobeNewswire Inc.Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFANASDAQ:PYXSPyxis Oncology Inc
08/03/202422:03Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PYXSPyxis Oncology Inc
07/03/202422:30GlobeNewswire Inc.Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024NASDAQ:PYXSPyxis Oncology Inc
05/03/202422:45GlobeNewswire Inc.Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual MeetingNASDAQ:PYXSPyxis Oncology Inc
27/02/202414:00GlobeNewswire Inc.Pyxis Oncology Announces $50 Million Private PlacementNASDAQ:PYXSPyxis Oncology Inc
06/12/202322:50Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PYXSPyxis Oncology Inc
28/11/202313:00GlobeNewswire Inc.Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical OfficerNASDAQ:PYXSPyxis Oncology Inc
07/11/202322:30GlobeNewswire Inc.Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate UpdateNASDAQ:PYXSPyxis Oncology Inc
27/10/202322:34Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:PYXSPyxis Oncology Inc
27/09/202315:18GlobeNewswire Inc.Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023NASDAQ:PYXSPyxis Oncology Inc
05/09/202323:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PYXSPyxis Oncology Inc
31/08/202322:01GlobeNewswire Inc.Pyxis Oncology to Participate in Two Upcoming Investment ConferencesNASDAQ:PYXSPyxis Oncology Inc
25/08/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PYXSPyxis Oncology Inc
23/08/202323:30Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:PYXSPyxis Oncology Inc
23/08/202323:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PYXSPyxis Oncology Inc
23/08/202323:28Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PYXSPyxis Oncology Inc
23/08/202314:35GlobeNewswire Inc.Pyxis Oncology Successfully Completes Acquisition of ApexigenNASDAQ:PYXSPyxis Oncology Inc
11/08/202313:26Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:PYXSPyxis Oncology Inc
11/08/202313:00GlobeNewswire Inc.Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate UpdateNASDAQ:PYXSPyxis Oncology Inc
01/08/202322:01GlobeNewswire Inc.Pyxis Oncology to Present at BTIG Virtual Biotechnology ConferenceNASDAQ:PYXSPyxis Oncology Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PYXS

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
G
Generali
BIT
NEXI
Nexi S.p.A
BIT
TIT
Telecom Italia
BIT
PST
Poste Italiane S.p.a
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network